University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Arie Perry, MD

Arie Perry, MD

Professor of Pathology and Neurological Surgery; Director of Neuropathology; Director of Neuropathology Fellowship Training Program; Vice Chair of Pathology

Cancer Center Program Memberships

Neurologic Oncology

Research Summary

My clinical interests focus most heavily on surgical neuropathology, especially in terms of its application towards neuro-oncology. As a diagnostic neuropathologist with a focus on CNS tumors, I am primarily involved in translational research with the primary goal of developing new diagnostic and prognostic markers, which can be utilized in the clinical management of brain tumor patients. In order to achieve this goal, my lab has applied immunohistochemical, molecular cytogenetic, and genomic screening techniques primarily towards the study of gliomas, meningiomas, and primitive pediatric malignancies. I have been particularly interested in improved classification and grading schemes as well as the identification of molecular genetic markers associated with tumorigenesis, malignant progression, and/or biologic behavior. I collaborate with a number of clinical and scientific researchers both within and outside UCSF and it is our hope that the markers we identify will improve patient management and lead to the development of novel therapeutic approaches. I also maintain a private consultation service for difficult surgical neuropathology cases obtained from the U.S. and abroad, particularly brain tumors.

Education

The University of Texas at Austin, TX, B.S., 1986, Zoology
UT Southwestern Medical Center, Dallas, TX, M.D., 1990, M.D.
UT Southwestern Medical Center, Dallas, TX, Postdoctoral, 1994, Anatomic and Clinical Pathology Residency
Mayo Clinic, Rochester, MN, Postdoctoral, 1998, Surgical Pathology, Neuropathology, and Research Fellowships


Professional Experience

  • 1997-1998
    Mayo Clinic School of Medicine Instructor Pathology
  • 1998-2003
    Washington U. School of Medicine Assistant Professor Pathology
  • 2003-2008
    Washington U. School of Medicine Associate Professor Pathology
  • 2008-2010
    Washington U. School of Medicine Professor Pathology
  • 2009-2010
    Washington U. School of Medicine Professor Neurosurgery
  • 2010-present
    University of California, San Francisco Professor Pathology
  • 2010-present
    University of California, San Francisco Professor Neurosurgery

Honors & Awards

  • 1993
    First Place Resident Award (poster): Texas Society of Pathologists meeting
  • 1994
    First Place Resident Award (podium): Texas Society of Pathologists meeting
  • 1994
    Matthew T. Moore Award, International Congress of Neuropathology meeting
  • 1995
    Mary Tom Award, Canadian Association of Neuropathologists meeting
  • 1995-1997
    Fellowship Research Award, American Brain Tumor Association
  • 1999
    Distinguished Service Teaching Award, WUSM (Medical School Class of 2001)
  • 2002
    Lucien J. Rubenstein Award, American Association of Neuropathologists meeting
  • 2002
    Distinguished Service Teaching Award, WUSM (Medical School Class of 2004)
  • 2004
    Distinguished Service Teaching Award, WUSM (Medical School Class of 2006)
  • 2005
    Professor of the Year Award, WUSM (Medical School Class of 2007)
  • 2006-now
    America’s Top Doctors and America's Top Doctors for Cancer (Castle Connolly)
  • 2007
    Distinguished Service Teaching Award, WUSM (Medical School Class of 2009)
  • 2008
    Professor of the Year Award, WUSM (Medical School Class of 2010)
  • 2009-now
    Best Doctors in America, U.S. News and World Reports
  • 2009
    Distinguished Service Teaching Award, WUSM (Medical School Class of 2011)
  • 2013
    Nominated for MS1 Essential Core Teaching Award, UCSF (MS Class of 2016)

Selected Publications

  1. Wood MD, Tihan T, Perry AJ, Chacko G, Turner C, Pu C, Payne C, Yu A, Bannykh S, Solomon DA. Multimodal molecular analysis of astroblastoma enables reclassification of most cases into more specific molecular entities. Brain Pathol. 2017 Sep 28.
    View on PubMed
  2. Mazor T, Chesnelong C, Pankov A, Jalbert LE, Hong C, Hayes J, Smirnov IV, Marshall R, Souza CF, Shen Y, Viswanath P, Noushmehr H, Ronen SM, Jones SJM, Marra MA, Cairncross JG, Perry A, Nelson SJ, Chang SM, Bollen AW, Molinaro AM, Bengtsson H, Olshen AB, Weiss S, Phillips JJ, Luchman HA, Costello JF. Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant IDH1. Proc Natl Acad Sci U S A. 2017 Sep 15.
    View on PubMed
  3. Chan AK, Han SJ, Choy W, Beleford D, Aghi MK, Berger MS, Shieh JT, Bollen AW, Perry A, Phillips JJ, Butowski N, Solomon DA. Familial melanoma-astrocytoma syndrome: synchronous diffuse astrocytoma and pleomorphic xanthoastrocytoma in a patient with germline CDKN2A/B deletion and a significant family history. Clin Neuropathol. 2017 Sep/Oct; 36(5):213-221.
    View on PubMed
  4. Pekmezci M, Cuevas-Ocampo AK, Perry A, Horvai AE. Significance of H3K27me3 loss in the diagnosis of malignant peripheral nerve sheath tumors. Mod Pathol. 2017 Aug 04.
    View on PubMed
  5. Chan E, Bollen AW, Sirohi D, Van Ziffle J, Grenert JP, Kline CN, Tihan T, Perry A, Gupta N, Solomon DA. Angiocentric glioma with MYB-QKI fusion located in the brainstem, rather than cerebral cortex. Acta Neuropathol. 2017 Aug 03.
    View on PubMed
  6. Banerjee A, Jakacki RI, Onar-Thomas A, Wu S, Nicolaides T, Young Poussaint T, Fangusaro J, Phillips J, Perry A, Turner D, Prados M, Packer RJ, Qaddoumi I, Gururangan S, Pollack IF, Goldman S, Doyle LA, Stewart CF, Boyett JM, Kun LE, Fouladi M. A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study. Neuro Oncol. 2017 Aug 01; 19(8):1135-1144.
    View on PubMed
  7. Sorge C, Li R, Singh S, Reddy AT, Solomon DA, Perry A, Friedman GK. Complete durable response of a pediatric anaplastic oligodendroglioma to temozolomide alone: Case report and review of literature. Pediatr Blood Cancer. 2017 Jul 11.
    View on PubMed
  8. Ferris SP, Hofmann JW, Solomon DA, Perry A. Characterization of gliomas: from morphology to molecules. Virchows Arch. 2017 Jul 04.
    View on PubMed
  9. Dahlin LB, Scherman P, Besjakov J, Lindberg E, Solomon DA, Horvai AE, Perry A. Intraneural glomus tumor of "uncertain malignant potential" and with BRAF mutation in the median nerve - an unusual case. Clin Neuropathol. 2017 Jul/Aug; 36(4):164-170.
    View on PubMed
  10. Miettinen MM, Antonescu CR, Fletcher CDM, Kim A, Lazar AJ, Quezado MM, Reilly KM, Stemmer-Rachamimov A, Stewart DR, Viskochil D, Widemann B, Perry A. Histopathologic Evaluation of Atypical Neurofibromatous Tumors and Their Transformation into Malignant Peripheral Nerve Sheath Tumor in Neurofibromatosis 1 Patients - A Consensus Overview. Hum Pathol. 2017 May 24.
    View on PubMed
  11. López G, Oberheim Bush NA, Berger MS, Perry A, Solomon DA. Diffuse non-midline glioma with H3F3A K27M mutation: a prognostic and treatment dilemma. Acta Neuropathol Commun. 2017 05 15; 5(1):38.
    View on PubMed
  12. Shankar GM, Abedalthagafi M, Vaubel RA, Merrill PH, Nayyar N, Gill CM, Brewster R, Bi WL, Agarwalla PK, Thorner AR, Reardon DA, Al-Mefty O, Wen PY, Alexander BM, van Hummelen P, Batchelor TT, Ligon KL, Ligon AH, Meyerson M, Dunn IF, Beroukhim R, Louis DN, Perry A, Carter SL, Giannini C, Curry WT, Cahill DP, Barker FG, Brastianos PK, Santagata S. Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. Neuro Oncol. 2017 04 01; 19(4):535-545.
    View on PubMed
  13. Pekmezci M, Rice T, Molinaro AM, Walsh KM, Decker PA, Hansen H, Sicotte H, Kollmeyer TM, McCoy LS, Sarkar G, Perry A, Giannini C, Tihan T, Berger MS, Wiemels JL, Bracci PM, Eckel-Passow JE, Lachance DH, Clarke J, Taylor JW, Luks T, Wiencke JK, Jenkins RB, Wrensch MR. Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. Acta Neuropathol. 2017 Jun; 133(6):1001-1016.
    View on PubMed
  14. Cuevas-Ocampo AK, Bollen AW, Goode B, Pajtler KW, Chavez L, Sharma T, Dai SC, McDermott M, Perry A, Korshunov A, Solomon DA. Genetic confirmation that ependymoma can arise as part of multiple endocrine neoplasia type 1 (MEN1) syndrome. Acta Neuropathol. 2017 Apr; 133(4):661-663.
    View on PubMed
  15. Wahl M, Phillips JJ, Molinaro AM, Lin Y, Perry A, Haas-Kogan DA, Costello JF, Dayal M, Butowski N, Clarke JL, Prados M, Nelson S, Berger MS, Chang SM. Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide. Neuro Oncol. 2017 02 01; 19(2):242-251.
    View on PubMed
  16. Neill E, Luks T, Dayal M, Phillips JJ, Perry A, Jalbert LE, Cha S, Molinaro A, Chang SM, Nelson SJ. Quantitative multi-modal MR imaging as a non-invasive prognostic tool for patients with recurrent low-grade glioma. J Neurooncol. 2017 Mar; 132(1):171-179.
    View on PubMed
  17. Louis DN, Aldape K, Brat DJ, Capper D, Ellison DW, Hawkins C, Paulus W, Perry A, Reifenberger G, Figarella-Branger D, Wesseling P, Batchelor TT, Cairncross JG, Pfister SM, Rutkowski S, Weller M, Wick W, von Deimling A. Announcing cIMPACT-NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy. Acta Neuropathol. 2017 01; 133(1):1-3.
    View on PubMed
  18. Winkler EA, Birk H, Safaee M, Yue JK, Burke JF, Viner JA, Pekmezci M, Perry A, Aghi MK, Berger MS, McDermott MW. Erratum to: Surgical resection of fourth ventricular ependymomas: case series and technical nuances. J Neurooncol. 2017 Jan; 131(2):423.
    View on PubMed
  19. Louis DN, Aldape K, Brat DJ, Capper D, Ellison DW, Hawkins C, Paulus W, Perry A, Reifenberger G, Figarella-Branger D, Wesseling P, Batchelor TT, Gregory Cairncross J, Pfister SM, Rutkowski S, Weller M, Wick W, von Deimling A. cIMPACT-NOW (the consortium to inform molecular and practical approaches to CNS tumor taxonomy): a new initiative in advancing nervous system tumor classification. Brain Pathol. 2016 Dec 20.
    View on PubMed
  20. Hirbe AC, Kaushal M, Sharma MK, Dahiya S, Pekmezci M, Perry A, Gutmann DH. Clinical genomic profiling identifies TYK2 mutation and overexpression in patients with neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Cancer. 2017 Apr 01; 123(7):1194-1201.
    View on PubMed

Go to UCSF Profiles, powered by CTSI